Regenerative Medicine

Creative Medical Technology (CELZ) secured USPTO patent allowance through 2040 for its ImmCelz™ therapy targeting heart failure and post-heart attack damage. The treatment, delivered via minimally invasive outpatient procedure, addresses a potential US patient population exceeding 11 million. While this significantly broadens the company’s regenerative medicine IP portfolio, the therapy remains in development and lacks FDA approval or current revenue.

Hemostemix’s ACP-01 therapy, a novel cellular treatment for heart failure, has been detailed in a peer-reviewed paper. Targeting non-ischemic dilated cardiomyopathy, ACP-01 utilizes autologous cells to combat inflammation, fibrosis, and improve blood flow. Earlier studies showed significant improvement in cardiac function, with LVEF increases up to 47.1% in DCM patients. The therapy is now available in Florida under new legislation, offering a promising option for patients with limited alternatives.